source
- Novo Nordisk sues Eli Lilly, alleging deceptive ads that misrepresent GLP-1 drug efficacyNovo Nordisk filed a lawsuit in federal court in New Jersey accusing Eli Lilly of running a deceptive advertising campaign. The complaint says Lilly’s ads compare the highest doses of its weight‑l…
- Jupiter Neurosciences signs $100M deal for U.S. rights to PharmAla's MDMA therapy ALA-002Jupiter Neurosciences announced a licensing agreement with Canadian biotech PharmAla Biotech to obtain U.S. rights to an MDMA‑based drug, ALA‑002, aimed at treating neuropsychiatric conditions. Th…